ライフサイエンスコーパス: aminotransferase

1 e 3 diarrhoea and grade 3 elevated aspartate aminotransferase).

2 or for diverse enzymes, among them aspartate aminotransferase.

3 ers such as increased level of serum alanine aminotransferase.

4 actate dehydrogenase, aspartate, and alanine aminotransferase.

5 okine concentration, cystatin C, and alanine aminotransferase.

6 ed Aedes aegypti mosquitoes requires alanine aminotransferase.

7 ls of alanine aminotransferase and aspartate aminotransferase.

8 oA, a pyridoxal 5'-phosphate (PLP)-dependent aminotransferase.

9 nsferase, and diaminobutyrate-2-oxoglutarate aminotransferase.

10 m mutations in the enzyme alanine-glyoxylate aminotransferase.

11 e < 100 U/L, below analyzer range; aspartate aminotransferase 0 hour, 15.6 +/- 9.3 U/L vs 7 hours, 24

12 f endogenous sulfur dioxide (SO2)/ aspartate aminotransferase 1 (AAT1) pathway in stretch-induced exc

13 ximum transcript abundance of Glu:glyoxylate aminotransferase 1 (GGT1) is regulated by intron-mediate

14 rate dehydrogenase (PHGDH) and phosphoserine aminotransferase 1 (PSAT-1), were recently highlighted b

15 ycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 1 (PSAT1), and phosphoserine phosphatas

16 nts vs six [1%] of 570), increased aspartate aminotransferase (103 [18%] vs 16 [3%]), hyperglycaemia

17 lanine aminotransferase (12%), and aspartate aminotransferase (11%).

18 ting (125 [66%]), and an increase in alanine aminotransferase (114 [60%]) in the ceritinib group and

19 is (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypophysitis

20 ents were increases in lipase (15%), alanine aminotransferase (12%), and aspartate aminotransferase (

21 old-stored DCD livers regarding peak alanine-aminotransferase (1239 vs 2065 U/L, P = 0.02), intrahepa

22 vs one [<1%] of 570) and increased aspartate aminotransferase (14 [2%] vs one [<1%]).

23 sus the placebo group were increased alanine aminotransferase (146 [25%] of 573 patients vs six [1%]

24 ng >/=2% of patients) were increased alanine aminotransferase (17 [3%] of 573 vs one [<1%] of 570) an

25 nts were transaminase increases (40% alanine aminotransferase, 17% aspartate aminotransferase), macul

26 Alanine-glyoxylate aminotransferase 2 (AGXT2) is the only enzyme capable of

27 Alanine-glyoxylate aminotransferase 2 (AGXT2) regulates systemic levels of

28 se, 22.67 U/L (19.94-25.41 U/L); for alanine aminotransferase, 21.77 U/L (18.96-24.59 U/L); for alkal

29 .80 mg/dL (39.84-45.76 mg/dL); for aspartate aminotransferase, 22.67 U/L (19.94-25.41 U/L); for alani

30 scalation included grade 3 increased alanine aminotransferase (240 mg daily) and grade 4 dyspnoea (30

31 (73 [30%] patients) and increased aspartate aminotransferase (25 [10%]).

32 ons in alanine aminotransferase or aspartate aminotransferase (25 [12%]).

33 vs 36.0 +/- 9.3 mg/dL; p </= 0.001), alanine aminotransferase (266.5 +/- 295.2 vs 861.8 +/- 813.7 U/L

34 induced significant improvement in aspartate aminotransferase (32.4 +/- 17.4 vs 21.5 +/- 6.9U/L), ala

35 (32.4 +/- 17.4 vs 21.5 +/- 6.9U/L), alanine aminotransferase (39.9 +/- 28.6U/L vs 23.8 +/- 14.1U/L),

36 pants developed a transaminase rise (alanine aminotransferase 4.5-5.9 times the upper limit of normal

37 a, those with CFLD had higher median alanine aminotransferase (42 versus 27, P = 0.005), aspartate am

38 with a FibroScan >6.8 kPa had higher alanine aminotransferase (42 versus 28U/L, P = 0.02), AST (35 ve

39 ransferase (65 [26%]), and increased alanine aminotransferase (47 [19%]).

40 nts vs four [3%] of 140), elevated aspartate aminotransferase (51 [18%] vs four [3%]), hyperglycaemia

41 b versus placebo group were elevated alanine aminotransferase (63 [22%] of 288 patients vs four [3%]

42 4%]), fatigue (83 [33%]), elevated aspartate aminotransferase (65 [26%]), and increased alanine amino

43 e more likely to have elevated serum alanine aminotransferase (72% vs. 50%; P < 0.01) and higher HBV

44 oratory abnormalities were increased alanine aminotransferase (73 [30%] patients) and increased aspar

45 Consistently, inhibition of aspartate-aminotransferase, a key enzyme of the shunt, inhibited n

46 ce accompanied by elevated levels of alanine aminotransferase, a marker of liver injury.

47 In aspartate aminotransferase (AAT), an extended hydrogen bond networ

48 SO2 synthase aspartate aminotransferase (AAT1 and AAT2) mRNA and protein expres

49 increased hepatic steatosis, plasma alanine aminotransferase activity, inflammation, oxidative stres

50 r mass, serum cholesterol, and serum alanine aminotransferase activity.

51 nd liver damage as measured by serum alanine aminotransferase activity.

52 ogy, propidium iodide injection, and alanine aminotransferase after IRI.

53 sis (Arabidopsis thaliana), the lysine (Lys) aminotransferase AGD2-LIKE DEFENSE RESPONSE PROTEIN1 (AL

54 glucose, alanine aminotransferase, aspartate aminotransferase, AGEs and insulin levels.

55 lycolate oxidase (GO) and alanine:glyoxylate aminotransferase (AGT) are both involved in the peroxiso

56 ncy of liver-peroxisomal alanine: glyoxylate aminotransferase (AGT), which allows glyoxylate oxidatio

57 aspartate aminotransferase, alanine aminotransferase (ALT), acute

58 liver tests (alkaline phosphatase, aspartate aminotransferase, alanine aminotransferase) and areas of

59 ional normalized ratio, bilirubin, aspartate aminotransferase, alanine aminotransferase) and liver hi

60 previous studies showing increased aspartate aminotransferase-alanine aminotransferase ratios, but, t

61 itrogen, we investigated the role of alanine aminotransferase (ALAT) in blood-fed Aedes aegypti.

62 ation in alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutam

63 OS cohort, E167K carriers had higher alanine aminotransferase ALT and lower lipid levels (P < 0.05),

64 tor-1 (markers for fibrinolysis) and alanine aminotransferase (ALT) (marker of ischemia-reperfusion [

65 ignificantly reduced serum levels of alanine aminotransferase (ALT) and liver steatosis and fibrosis,

66 aspartate aminotransferase (AST) or alanine aminotransferase (ALT) elevation with fevers, and grade

67 ccurrence of at least 1 flare in the alanine aminotransferase (ALT) level (>200 U/L; P = .007).

68 as viral DNA levels >2000 IU/mL and alanine aminotransferase (ALT) levels >80 U/mL, respectively.

69 brosis, inflammation, steatosis, and alanine aminotransferase (ALT) levels and viscoelastic and diffu

70 ury is identified internationally by alanine aminotransferase (ALT) levels equal to or exceeding 5x t

71 ulin, fasting serum lipids and serum alanine aminotransferase (ALT) levels were measured and an abdom

72 tional studies of the association of alanine aminotransferase (ALT) levels with ischaemic heart disea

73 Alanine aminotransferase (ALT) predicts type 2 diabetes but it i

74 APRI), fibrosis-4 index (FIB-4), AST/alanine aminotransferase (ALT) ratio (AAR), and age-platelet ind

75 CatD and alanine aminotransferase (ALT) were measured in plasma.

76 aspartate aminotransferase, alanine aminotransferase (ALT), acute kidney injury (AKI), model

77 causal effects of the liver enzymes, alanine aminotransferase (ALT), alkaline phosphatase (ALP) and g

78 reatment substantially reduced serum alanine aminotransferase (ALT), alkaline phosphatase (AST), tota

79 ng gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (

80 Alanine aminotransferase (ALT), aspartate aminotransferase (AST)

81 Alanine aminotransferase (ALT), aspartate aminotransferase (AST)

82 gical changes and increases in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST)

83 Alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT)

84 Also, we assessed serum levels of alanine-aminotransferase (ALT), liver histology, hepatic triglyc

85 high aspartate (AST, >49.9 IU/L) and alanine aminotransferase (ALT, >56.1 IU/L), to the relationships

86 nterval [CI]: 1.72-3.36; P < 0.001), alanine aminotransferase (ALT; OR, 1.24; 95% CI: 1.12-1.38; P <

87 reatment beyond the standard course (alanine aminotransferase [ALT] activity >100 U/L).

88 e classified as presumed NAFLD (pNF; alanine aminotransferase [ALT] level >/= 20 for women or >/= 31

89 d as (age x AST)/(platelet x radical alanine aminotransferase [ALT]).

90 Hepatitis Cohort Study, 78% had >/=1 alanine aminotransferase and 37% had >/=1 hepatitis B virus DNA

91 ace antigen, and 97% of patients had alanine aminotransferase and 44% had hepatitis B virus DNA testi

92 decreases of 53% (p < 0.05) in serum alanine aminotransferase and 74% (p < 0.05) in hepatic triglycer

93 ng toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase and one gr

94 reflected by reductions in plasma aspartate aminotransferase and alanine aminotransferase concentrat

95 ased platelet count, and increased aspartate aminotransferase and alpha-fetoprotein levels were assoc

96 in liver and serum BA levels, serum alanine aminotransferase and aspartate aminotransferase levels,

97 oon degeneration, and elevated serum alanine aminotransferase and aspartate aminotransferase levels.

98 mg twice a day (grade 3 increase of alanine aminotransferase and aspartate aminotransferase) and two

99 ations in liver; and serum levels of alanine aminotransferase and aspartate aminotransferase.

100 rated 40% and 45% decrease in plasma alanine aminotransferase and BA levels, respectively.

101 ate (GFR) but also caused more elevations in aminotransferase and bilirubin levels.

102 weight, blood cell counts, and serum alanine aminotransferase and creatinine.

103 0), in combination with elevation of alanine aminotransferase and gamma-glutamyl transferase, two mar

104 ated by lower levels of TCDD-induced alanine aminotransferase and hepatic triglycerides.

105 st common of which were increases in alanine aminotransferase and in aspartate aminotransferase, and

106 Aspartate aminotransferase and lactate dehydrogenase as injury mar

107 NEL) staining, circulating levels of alanine aminotransferase and lactate dehydrogenase, and inflamma

108 ing each significantly reduced serum alanine aminotransferase and liver mRNA expression of tumor necr

109 ted APAP-induced serum elevations of alanine aminotransferase and microRNA-122 and completely abrogat

110 No patients had elevations in alanine aminotransferase and no patients prematurely discontinue

111 eased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipase).

112 sitive associations between elevated alanine aminotransferase and pretreatment IP-10 and between the

113 Median alanine aminotransferase and serum HBV DNA levels were 2544 U/L

114 Serum levels of alanine aminotransferase and tumor necrosis factor-alpha, and li

115 ated by a specialized isoform of cytoplasmic aminotransferase and, importantly, reveals an immunomodu

116 ild phenotype of hepatic steatosis, elevated aminotransferases and alkaline phosphatase, and hypercho

117 tigated the relationships between liver fat, aminotransferases and hepatic architecture in liver biop

118 ent was associated with grade 3 increases in aminotransferases and the study was stopped early.

119 phatase, aspartate aminotransferase, alanine aminotransferase) and areas of liver parenchymal necrosi

120 lirubin, aspartate aminotransferase, alanine aminotransferase) and liver histology (hematoxylin-eosin

121 se of alanine aminotransferase and aspartate aminotransferase) and two (13%) patients given 300 mg tw

122 notypes (with early-onset NAFLD vs. very low aminotransferases) and then in a large validation cohort

123 ematocrit, albumin, total protein, aspartate aminotransferase), and baseline demographics and estimat

124 s, including alkaline phosphatase, aspartate aminotransferase, and bilirubin, were significantly high

125 in alanine aminotransferase and in aspartate aminotransferase, and hyponatraemia, each occurring in t

126 necrosis, infiltrating CD8(+) cells, alanine aminotransferase, and proinflammatory cytokines.

127 , dyspnoea, hyponatraemia, increased alanine aminotransferase, and thrombocytopenia (three [1%] each)

128 bone-derived alkaline phosphatase, elevated aminotransferases, and elevated cholesterol, in combinat

129 ndex (FIB-4), which is calculated using age, aminotransferases, and platelets.

130 ve clinical variables and revealed aspartate aminotransferase as an important, albeit previously unde

131 PLP in both GabR and a homologous aspartate aminotransferase (Asp-AT) from Escherichia coli as a con

132 ignificantly reduced plasma glucose, alanine aminotransferase, aspartate aminotransferase, AGEs and i

133 fected patients was the elevation in alanine aminotransferase, aspartate aminotransferase, alkaline p

134 th lower serum alkaline phosphatase; alanine aminotransferase; aspartate aminotransferase; gamma-glut

135 Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and fetuin-A were determined in f

136 ating characteristics curve showed aspartate aminotransferase (AST) had highest area under the curve

137 ng, lower platelet count, elevated aspartate aminotransferase (AST) level, positivity in the nonstruc

138 h grade 3 rash and fevers, grade 4 aspartate aminotransferase (AST) or alanine aminotransferase (ALT)

139 um alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and g

140 lanine aminotransferase (ALT), and aspartate aminotransferase (AST), among a discovery set of 731 par

141 Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyltransferase (G

142 Transplant albumin, day-1 aspartate aminotransferase (AST), day-1 lactate, day-3 bilirubin,

143 Aspartate aminotransferase (AST)-to-platelet ratio (APRI) was calc

144 aluated the diagnostic accuracy of aspartate aminotransferase (AST)-to-platelet ratio index (APRI), f

145 sferase (42 versus 27, P = 0.005), aspartate aminotransferase (AST; 26 versus 21, P = 0.01), direct b

146 io (APRI) was calculated as = 100*(aspartate aminotransferase [AST]/upper limit of AST)/platelet.

147 IL28B non-CC, and had a lower serum alanine aminotransferase at baseline than non-black patients.

148 05-0.49; P = 0.01), normal levels of alanine aminotransferase at the end of intervention (OR = 9.84,

149 t-generation gamma-amino butyric acid (GABA)-aminotransferase (AT) inhibitor, shows comparable pharma

150 ssential E. coli enzymes: the branched-chain aminotransferase BCAT and the DNA replication initiator

151 Branched-chain aminotransferases (BCAT) are enzymes that initiate the c

152 t inhibitors of mitochondrial branched-chain aminotransferase (BCATm) based on a 2-benzylamino-pyrazo

153 Inhibitors of mitochondrial branched chain aminotransferase (BCATm), identified using fragment scre

154 he kynurenine-3-monooxygenase and kynurenine aminotransferase branches of the kynurenine pathway are

155 ncluding XDH1, glutamine synthetase, alanine aminotransferase, catalase, superoxide dismutase, ornith

156 s, inflammation, and serum levels of alanine aminotransferase compared with mice given a control vect

157 ated lipase level (15; 5%), elevated alanine aminotransferase concentration (12; 4%), and abdominal p

158 [21%] vs one [1%]), and increased aspartate aminotransferase concentration (16 [14%] vs one [1%] in

159 n the ceritinib group were increased alanine aminotransferase concentration (24 [21%] of 115 vs two [

160 one [1%]) and increased alanine or aspartate aminotransferase concentration (39 [10%] vs none).

161 One patient was ineligible (alanine aminotransferase concentration was above the required ra

162 Elevated alanine and aspartate aminotransferase concentrations and profound elevations

163 Metabolite profiling showed that serum aminotransferase concentrations are a signature of liver

164 centrations of >20 000 IU/mL), serum alanine aminotransferase concentrations of greater than 60 U/L i

165 Elevations of aspartate and alanine aminotransferase concentrations of three or more times t

166 lasma aspartate aminotransferase and alanine aminotransferase concentrations; hepatic steatosis; and

167 ferredoxin-dependent glutamine oxoglutarate aminotransferases declined significantly in the nfu3 mut

168 n the group given placebo; levels of alanine aminotransferase decreased 21%-35% on average among subj

169 some patients with abnormal levels of serum aminotransferases, despite SVR12 to DAAs for HCV infecti

170 who achieved SVR12 (n = 14), serum levels of aminotransferases did not normalize during or after DAA

171 grade 3 dermatitis (five patients), grade 3 aminotransferase elevation (seven patients), grade 3 dia

172 ed, including 1 case of asymptomatic alanine aminotransferase elevation.

173 vation in this cohort exhibited peak alanine aminotransferase elevations >2 times the upper limit of

174 lone, statin initiators had reduced risks of aminotransferase elevations (HR, 0.57 [95% CI, .45-.72])

175 grade 1 corneal toxicity [n = 1] and grade 3 aminotransferase elevations [n = 1]).

176 toxicities in four patients (100 mg, grade 3 aminotransferase elevations [n = 1]; 125 mg, hyperphosph

177 There were no notable differences in aminotransferase elevations in the deferred treatment gr

178 Limited, asymptomatic, and transient alanine aminotransferase elevations in the low-dose (n = 1) and

179 It is important to monitor maternal aminotransferase elevations postpartum.

180 HIV-infected adults with chronic aminotransferase elevations while receiving ART have a h

181 mbocytopenia (five [28%]), increased alanine aminotransferase (five [28%]), and hypokalaemia (four [2

182 hosphokinase (seven [8%]), increased alanine aminotransferase (five [6%]), and increased aspartate am

183 e followed up on a monthly basis for alanine aminotransferase followed by quantitative HBV DNA testin

184 Here we show that BCAT1, a cytosolic aminotransferase for branched-chain amino acids (BCAAs),

185 sferase (five [6%]), and increased aspartate aminotransferase (four [5%]).

186 tes transcription of gamma-aminobutyric acid aminotransferase (GABA-AT; GabT) upon interactions with

187 phatase; alanine aminotransferase; aspartate aminotransferase; gamma-glutamyltransferase; and, in wom

188 The aspartate aminotransferase gene AAT1 was found to be a common memb

189 oration by the next-generation sequencing of aminotransferase genes (n = 96).

190 teria (alanine aminotransferase or aspartate aminotransferase greater than three times the ULN and to

191 We determined development of (1) liver aminotransferases >200 U/L, (2) severe ALI (coagulopathy

192 unt (HR 2.45, p 0.011), raised serum alanine aminotransferase (HR 4.22, p 0.016), raised serum total

193 nurenine monooxygenase (KMO), and kynurenine aminotransferase II (KAT II).

194 , aspartate aminotransferase in 70%, alanine aminotransferase in 54%, and creatinine kinase in 46%.

195 s of lactate dehydrogenase in 82%, aspartate aminotransferase in 70%, alanine aminotransferase in 54%

196 atients at 20 mg/kg, and increased aspartate aminotransferase in one patient at 1 mg/kg, and one pati

197 We also measured levels of TNF and alanine aminotransferase in serum from mice.

198 Patients with elevated alanine aminotransferase in specialty care were more likely to r

199 Median peak aspartate aminotransferase in the first 7 days was significantly l

200 se in two (8%) patients, increased aspartate aminotransferase in two (8%) patients, decreased platele

201 on in four (15%) patients, increased alanine aminotransferase in two (8%) patients, increased asparta

202 HDV co-infection and normalisation of serum aminotransferases in a high proportion of patients 1 yea

203 We aimed to explore the role of liver aminotransferases in nonalcoholic fatty liver disease (N

204 te, which inhibits the enzymatic activity of aminotransferases including GPT2, suppresses xenograft t

205 iver gene- and protein-expression changes of aminotransferases, including their corresponding isoform

206 g in more than two patients included alanine aminotransferase increase (five [14%]), pyrexia (four [1

207 se events were pyrexia (four [11%]), alanine aminotransferase increase (four [11%]), hypertension (fo

208 fatigue (three [1%] vs seven [3%]), alanine aminotransferase increase (three [1%] vs four [2%]), and

209 five [14%]), pyrexia (four [11%]), aspartate aminotransferase increase (three [8%]), and ejection fra

210 atine phosphokinase increase in one patient, aminotransferase increase in one patient, and blood chol

211 tative HBV DNA testing in those with alanine aminotransferase increase.

212 ): enterocolitis, infusion-related reaction, aminotransferases increased, chondrocalcinosis, synoviti

213 ients, with pneumonitis, increased aspartate aminotransferase, increased alanine aminotransferase, ra

214 tients, statin initiators had lower risks of aminotransferase increases (HR, 0.52 [95% CI, .40-.66]),

215 lly reversible, asymptomatic grade 3 alanine aminotransferase increases (one on 50 mg, two on 200 mg)

216 ith the most common grade three events being aminotransferase increases and neutropenia, each of whic

217 WecE is a sugar aminotransferase involved in the biosynthesis of enterob

218 y as determined by serum creatinine, alanine aminotransferase, lactate dehydrogenase, and creatine ki

219 Elevations in the alanine aminotransferase level (to >3 times the upper limit of t

220 y, diabetes, sex, age, and change in alanine aminotransferase level and change in FIB-4 index.

221 nt each of grade 4 adverse events of alanine aminotransferase level elevation and rectal hemorrhage.

222 event was an elevation in the serum alanine aminotransferase level to 1.5 times the upper limit of t

223 arily those with a higher ratio of aspartate aminotransferase level to platelet count.

224 Elevations in the aminotransferase level were reversible after stopping to

225 tients, statin initiators had lower risks of aminotransferase levels >200 U/L (HR, 0.66 [95% CI, .53-

226 titis C virus, persons with elevated alanine aminotransferase levels (>/=19 IU/L for women and >/=30

227 penia (70 [14%] of 490), increased aspartate aminotransferase levels (22 [5%]), and anaemia (19 [4%])

228 ea (19 [8%] vs two [1%]), and raised alanine aminotransferase levels (two [1%] vs 19 [8%]).

229 however, had significant reductions in serum aminotransferase levels and lobular inflammation.

230 ted by decreased serum alanine and aspartate aminotransferase levels and numbers of TUNEL-positive ce

231 lar severity of NASH, suggesting that plasma aminotransferase levels are misleading parameters for gu

232 Abnormal alanine aminotransferase levels at admission can indicate the pr

233 Americans (all P < 0.05), with high alanine aminotransferase levels in Hispanics (P < 0.05) and a mo

234 Alanine aminotransferase levels increased in ALGS after PEBD (18

235 Elevated serum aminotransferase levels occurred in 4 patients and were

236 f the 6 patients (67%) had increased alanine aminotransferase levels of more than 1.5 times the upper

237 Aminotransferase levels peaked at a median of 9 days aft

238 of 22 patients (18%) with increased alanine aminotransferase levels showed positive reactivity on HE

239 serum alanine aminotransferase and aspartate aminotransferase levels, and hepatic inflammation.

240 ntly associated with HBV DNA load, aspartate aminotransferase levels, and platelet counts; 13 of 106

241 rase levels, four (33%) had raised aspartate aminotransferase levels, and two (17%) had increased bil

242 Notably, increases in alanine aminotransferase levels, apoptotic markers, and human in

243 Five (42%) patients had raised alanine aminotransferase levels, four (33%) had raised aspartate

244 injury dramatically decreased serum alanine aminotransferase levels, histological injury, the number

245 oration of ferritin, fibrinogen, and alanine aminotransferase levels.

246 serum alanine aminotransferase and aspartate aminotransferase levels.

247 ssessed by hematoxylin and eosin and alanine aminotransferase levels.

248 kines and a marker of liver failure (alanine aminotransferase); liver tissues were collected and anal

249 nor in 100 healthy individuals with alanine aminotransferase <22/20 IU/mL.

250 (40% alanine aminotransferase, 17% aspartate aminotransferase), maculopapular rash (17%), and neutrop

251 ancer-associated NQO1 and alanine:glyoxylate aminotransferase, mutated in primary hyperoxaluria type

252 cluding leg cramps (n = 2), elevated alanine aminotransferase (n = 2), diarrhea (n = 1), and nausea/a

253 phosphokinase (n=2), and increased aspartate aminotransferase (n=2) each occurring in more than one p

254 ade 3-4 adverse events were grade 3 elevated aminotransferases (n=1 [6%]) in the melanoma cohort, and

255 therapy compared to placebo improved alanine aminotransferase normalization (risk ratio [RR] = 2.3, 9

256 nversion (RR = 2.1, 95% CI 1.3-3.5), alanine aminotransferase normalization (RR = 1.4, 95% CI 1.1-1.7

257 HBV DNA suppression and frequency of alanine aminotransferase normalization and HBeAg seroconversion.

258 eclined upon viremia suppression and alanine aminotransferase normalization induced by NUC therapy.

259 luding weight loss, type 2 diabetes, alanine aminotransferase normalization, age, and a nonalcoholic

260 of 1 year follow-up, normalisation of serum aminotransferases occurred in nine of 12 patients.

261 ic acid (IAA) biosynthesis enzyme TRYPTOPHAN AMINOTRANSFERASE OF ARABIDOPSIS1, the auxin transporter

262 int was incidence of hepatotoxicity: alanine aminotransferase of greater than five times the upper li

263 d anti-HBs gain, with normalization of serum aminotransferases off therapy.

264 5 [22%] patients), and elevations in alanine aminotransferase or aspartate aminotransferase (25 [12%]

265 it of normal (ULN) or Hy's criteria (alanine aminotransferase or aspartate aminotransferase greater t

266 rations of asymptomatic alanine or aspartate aminotransferase, or gamma-glutamyltransferase, without

267 levels of blood lactate (P = 0.007), alanine aminotransferase (P = 0.027), bilirubin (P = 0.005), and

268 higher celiac antibody (p < 0.001), alanine aminotransferase (p = 0.035) and thyroid-stimulating hor

269 age, using validated serum fibrosis markers, aminotransferase platelet ratio index (APRI) and fibrosi

270 A risk score according to age, sex, alanine aminotransferase, previous chronic liver disease, family

271 Instead, we identified a putative aromatic aminotransferase (PsArAT) from pea that may function in

272 ntrol the electronic modulation in aspartate aminotransferase.Pyridoxal 5'-phosphate (PLP) is a ubiqu

273 spartate aminotransferase, increased alanine aminotransferase, rash, and dyspnoea being the most comm

274 increased aspartate aminotransferase-alanine aminotransferase ratios, but, to date, has not been conf

275 in the placebo group; P = .02) and aspartate aminotransferase (reduction, 31 +/- 52 vs 4 +/- 36 U/L i

276 ary outcomes: reduced mean levels of alanine aminotransferase (reduction, 53 +/- 88 U/L vs 8 +/- 77 U

277 coding mitochondrial and cytosolic aspartate aminotransferases, respectively; (iii) MDH1 and MDH2 enc

278 urface antigen (HBsAg), HBV DNA, and alanine aminotransferase results obtained while on DAA treatment

279 t, serum chemistry profile, level of alanine aminotransferase, rheumatoid factor activity, C4 fractio

280 patic triglyceride accumulation, circulating aminotransferases rise as a consequence of the need for

281 g >/=2% of patients) were elevated aspartate aminotransferase (six [2%] vs none), dyspnoea (six [2%]

282 ]), and increased concentration of aspartate aminotransferase (six [3%] vs two [2%]).

283 pled receptor 5-positive (Lgr5) and Tyrosine aminotransferase (TAT).

284 TH), and tyrosine is catabolized by tyrosine aminotransferase (TAT).

285 [13%] of 94 patients) and increased alanine aminotransferase (ten [11%]) in the combination group an

286 nd hepatitis flare as an increase in alanine aminotransferase to >/=3 times the upper limit of normal

287 3 times the upper limit of normal, aspartate aminotransferase to platelet ratio index score >/=1.5, h

288 r fibrosis was predicted using the aspartate aminotransferase-to-platelet ratio index (APRI), fibrosi

289 d liver fibrosis defined using the aspartate aminotransferase-to-platelet ratio index (APRI).

290 serum by >98%, and decreased plasma alanine aminotransferase, total bilirubin, and serum alkaline ph

291 relevant laboratory abnormalities in alanine aminotransferase, total bilirubin, or hemoglobin were ob

292 gait disturbance (one event), elevated liver aminotransferases (two events in two patients, one with

293 Aspartate aminotransferase was significantly higher in DCD recipie

294 nscriptional level and enzymatic activity of aminotransferases was included.

295 markers lactate dehydrogenase and aspartate aminotransferase were persistently low (lactate dehydrog

296 ilitates the breakdown of alanine by alanine aminotransferase when reoxygenation occurs.

297 homodimeric PLP-dependent enzyme, aspartate aminotransferase, which was reacted in situ with alpha-m

298 iated with a deregulated liver expression of aminotransferases, which was unrelated to the disease se

299 international normalized ratio, and alanine aminotransferase within 3 days posttransplant.

300 MC-2 in HS also decreased levels of alanine aminotransferase, zonula occludens-1, and interleukin-1b